Gilead Sciences has announced the appointment of Daniel O’Day as CEO, following the departure in 2013 of CEO John Milligan. O’Day joins Gilead from Switzerland’s Roche Holding, where he was most recently responsible for the company’s pharmaceuticals group. His new role will see him seeking fresh acquisitions and research and development deals for Gilead, amid declining sales of the firm’s hepatitis C drugs, while also focusing on its recent investment in CAR-T cancer treatment therapies.
Gilead Sciences has announced the appointment of Daniel O’Day as CEO, following the departure in July of CEO John Milligan. O’Day joins Gilead from Switzerland’s Roche Holding, where he was most recently responsible for the company’s pharmaceuticals group. His new role will see him seeking fresh acquisitions and research and development deals for Gilead, amid declining sales of the firm’s hepatitis C drugs, while also focusing on its recent investment in CAR-T cancer treatment therapies.